Kangtai Bio kicks off phase II trial for vaccine

Shenzhen Kangtai Biological Products Co., Ltd. [SZSE:300601] announced that its wholly-owned subsidiary, Beijing Minhai Biotechnology Co., Ltd., has initiated Phase II clinical trials for its 20-valent pneumococcal polysaccharide conjugate vaccine. The trial has successfully enrolled its first subject. The vaccine is intended for infants and children aged 2 months to 5 years to prevent invasive diseases caused by 20 pneumococcal serotypes. The Phase II trial employs a randomized, blinded, positive-controlled design to evaluate the safety and immunogenicity in a healthy population. According to the announcement, the commencement of the Phase II trial represents a significant milestone in the vaccine's development. The company noted that currently, Pfizer is the only company with a 20-valent pneumococcal polysaccharide conjugate vaccine approved outside of China.